Cefoperazone sodium

Names

[ Name ]:
Cefoperazone sodium

[Synonym ]:
Cefoperazone sodium
MFCD07793331
5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2R)-2-[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, sodium salt, (6R,7R)- (1:1)
Sodium (6R,7R)-7-{[(2R)-2-{[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino}-2-(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
Sodium (6R,7R)-7-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
cefoperazone-Na
Natrium-(6R,7R)-7-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-2-carboxylat
Sodium cefoperazone
cefoperazone monosodium
EINECS 263-751-5
Tomabef
cephoperazone sodium
Cefoperazone sodium [USAN:JAN]
Cefoperazone sodium salt
CEFOBID IN PLASTIC CONTAINER
T 1551
Cefoperazone sodium (JP15/USP)
Cefoperazonesodium
Cefoperazone (sodium salt)

Biological Activity

[Description]:

Cefoperazone sodium salt is a cephalosporin antibiotic for inhibition of rMrp2-mediated [3H]E217βG uptake with IC50 of 199 μM.Target: AntibacterialCefoperazone is a sterile, semisynthetic, broad-spectrum, parenteral cephalosporin antibiotic for intravenous or intramuscular administration. After intravenous administration of 2 g of Cefoperazone, levels in serum rang from 202μg/mL to 375 μg/mL depending on the period of drug administration. After intramuscular injection of 2 g of Cefoperazone, the mean peak serum level is 111 μg/mL at 1.5 hours. At 12 hours after dosing, mean serum levels are still 2 to 4 μg/mL. Cefoperazone is 90% bound to serum proteins.

[Related Catalog]:

Signaling Pathways >> Anti-infection >> Bacterial

Research Areas >> Infection

[References]

[1]. Kato, Y., et al., Involvement of multidrug resistance-associated protein 2 (Abcc2) in molecular weight-dependent biliary excretion of beta-lactam antibiotics. Drug Metab Dispos, 2008. 36(6): p. 1088-96.

[2]. Craig, W.A. and A.U. Gerber, Pharmacokinetics of cefoperazone: a review. Drugs, 1981. 22 Suppl 1: p. 35-45.

[Related Small Molecules]

Chemical & Physical Properties

[ Melting Point ]:
200-202°C

[ Molecular Formula ]:
C₂₅H₂₆N₉NaO₈S₂

[ Molecular Weight ]:
667.649

[ Exact Mass ]:
667.124329

[ PSA ]:
273.69000

[ Water Solubility ]:
H2O: 50 mg/mL, clear, faintly yellow

MSDS

Click to get detail MSDS

Safety Information

[ Symbol ]:

GHS08

[ Signal Word ]:
Danger

[ Hazard Statements ]:
H317-H334

[ Precautionary Statements ]:
P261-P280-P342 + P311

[ Hazard Codes ]:
Xn:Harmful

[ Risk Phrases ]:
R42/43

[ Safety Phrases ]:
S22-S36/37

[ RIDADR ]:
NONH for all modes of transport

[ WGK Germany ]:
2

[ RTECS ]:
XI0374000

[ HS Code ]:
2941905600

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

DownStream

Customs

[ HS Code ]: 2941905600

Articles

Housing conditions modulate the severity of Mycoplasma pulmonis infection in mice deficient in class A scavenger receptor.

Comp. Med. 64(6) , 424-39, (2014)

Mycoplasmosis is a frequent causative microbial agent of community-acquired pneumonia and has been linked to exacerbation of chronic obstructive pulmonary disease. The macrophage class A scavenger rec...

Randomized comparison of piperacillin-tazobactam plus amikacin versus cefoperazone-sulbactam plus amikacin for management of febrile neutropenia in children with lymphoma and solid tumors.

Pediatr. Hematol. Oncol. 30(2) , 141-8, (2013)

The objective of this study was to compare the effectiveness of piperacillin-tazobactam (PIP/TAZO) plus amikacin (AMK) (PIP/TAZO+AMK) versus cefoperazone-sulbactam (CS) plus AMK (CS+AMK) for the treat...

Interaction between caspofungin or voriconazole and cefoperazone-sulbactam or piperacillin-tazobactam by in vitro and in vivo methods.

APMIS 122(5) , 412-7, (2014)

Immunosuppressive patients are at risk of fungal and bacterial infections. Therefore, these patients receive prophylactic, preemptive, empirical or target antifungal and concomitant antibiotic therapy...